RANCHO CORDOVA, Calif.,
Feb. 17, 2021 /PRNewswire/ --
ThermoGenesis Holdings, Inc. ("ThermoGenesis" or the
"Company") (Nasdaq: THMO), a market leader in automated cell
processing tools and services in the cell and gene therapy field,
announced today that the Company will kick off a year of
celebration of its 35th anniversary by aligning its future
corporate strategy in offering cell processing systems and services
to meet the large-scale cellular manufacturing needs of the
increasing number of therapies to be developed over the next
decade.
ThermoGenesis has built a solid reputation in the cell banking
and cell therapy field. The Company was originally founded in 1986
during a pivotal time, when the stem cell and gene therapy industry
was in its infancy. In the early-1990s, ThermoGenesis' original
founder, Phil Coelho, formed a
long-term collaboration with Dr. Pablo
Rubinstein of the New York Blood Center, the father of all
cord blood stem cell banking. Together, they invented, patented,
and obtained FDA clearance for the first "functionally closed"
system for concentrating and isolating stem cells from fresh cord
blood samples as well as the protocol for long term
cryopreservation of those stem cells to insure retrieval decades
later. These breakthrough methods were widely adopted and enabled
the cord blood banking industry to grow, expand, and become
commercially viable today.
These earliest inventions and protocols were followed by the
launch of ThermoGenesis' fully automated BioArchive® smart
cryopreservation system in 1999 and later its AXP® automated cell
harvesting system in 2005. These fully automated systems have been
adopted by over 130+ leading cord blood transplant centers and
other stem cell institutes – such as MD Anderson, Cleveland Clinic,
Duke University, New York Blood Center
– in 40+ countries. These systems remain "state-of-the-art" almost
20 years later.
"In the past 20 years, ThermoGenesis and its affiliated
companies have helped to advance and shape the landscape of the
cell banking industry," said Chris
Xu, PhD, Chief Executive Officer of ThermoGenesis. "Cell
based therapies have become one of the fastest growing sectors in
medicine – with over 1,000 clinical trials underway in CAR-T cell
therapy alone. As we enter the Company's 35th anniversary, we
remain committed to staying as the world's leading technology
provider for the cell and gene therapy field."
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and
markets a range of automated technologies for CAR-T and other
cell-based therapies. The Company currently markets a full suite of
solutions for automated clinical biobanking, point-of-care
applications, and automated processing for immuno-oncology,
including its semi-automated, functionally-closed
CAR-TXpress™ platform, which streamlines the manufacturing
process for the emerging CAR-T immunotherapy market. For more
information about ThermoGenesis, please
visit: www.ThermoGenesis.com.
Company Contact:
Wendy
Samford
916-858-5191
ir@ThermoGenesis.com
Investor Contact:
Paula Schwartz, Rx
Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/thermogenesis-holdings-begins-a-year-of-celebration-of-its-35th-anniversary-in-the-cell-banking-and-cell-therapy-industry-301229801.html
SOURCE ThermoGenesis Holdings, Inc.